Cargando…
Cancer vaccines as promising immuno-therapeutics: platforms and current progress
Research on tumor immunotherapy has made tremendous progress in the past decades, with numerous studies entering the clinical evaluation. The cancer vaccine is considered a promising therapeutic strategy in the immunotherapy of solid tumors. Cancer vaccine stimulates anti-tumor immunity with tumor a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931585/ https://www.ncbi.nlm.nih.gov/pubmed/35303904 http://dx.doi.org/10.1186/s13045-022-01247-x |
_version_ | 1784671297009090560 |
---|---|
author | Liu, Jian Fu, Minyang Wang, Manni Wan, Dandan Wei, Yuquan Wei, Xiawei |
author_facet | Liu, Jian Fu, Minyang Wang, Manni Wan, Dandan Wei, Yuquan Wei, Xiawei |
author_sort | Liu, Jian |
collection | PubMed |
description | Research on tumor immunotherapy has made tremendous progress in the past decades, with numerous studies entering the clinical evaluation. The cancer vaccine is considered a promising therapeutic strategy in the immunotherapy of solid tumors. Cancer vaccine stimulates anti-tumor immunity with tumor antigens, which could be delivered in the form of whole cells, peptides, nucleic acids, etc. Ideal cancer vaccines could overcome the immune suppression in tumors and induce both humoral immunity and cellular immunity. In this review, we introduced the working mechanism of cancer vaccines and summarized four platforms for cancer vaccine development. We also highlighted the clinical research progress of the cancer vaccines, especially focusing on their clinical application and therapeutic efficacy, which might hopefully facilitate the future design of the cancer vaccine. |
format | Online Article Text |
id | pubmed-8931585 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-89315852022-03-18 Cancer vaccines as promising immuno-therapeutics: platforms and current progress Liu, Jian Fu, Minyang Wang, Manni Wan, Dandan Wei, Yuquan Wei, Xiawei J Hematol Oncol Review Research on tumor immunotherapy has made tremendous progress in the past decades, with numerous studies entering the clinical evaluation. The cancer vaccine is considered a promising therapeutic strategy in the immunotherapy of solid tumors. Cancer vaccine stimulates anti-tumor immunity with tumor antigens, which could be delivered in the form of whole cells, peptides, nucleic acids, etc. Ideal cancer vaccines could overcome the immune suppression in tumors and induce both humoral immunity and cellular immunity. In this review, we introduced the working mechanism of cancer vaccines and summarized four platforms for cancer vaccine development. We also highlighted the clinical research progress of the cancer vaccines, especially focusing on their clinical application and therapeutic efficacy, which might hopefully facilitate the future design of the cancer vaccine. BioMed Central 2022-03-18 /pmc/articles/PMC8931585/ /pubmed/35303904 http://dx.doi.org/10.1186/s13045-022-01247-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Liu, Jian Fu, Minyang Wang, Manni Wan, Dandan Wei, Yuquan Wei, Xiawei Cancer vaccines as promising immuno-therapeutics: platforms and current progress |
title | Cancer vaccines as promising immuno-therapeutics: platforms and current progress |
title_full | Cancer vaccines as promising immuno-therapeutics: platforms and current progress |
title_fullStr | Cancer vaccines as promising immuno-therapeutics: platforms and current progress |
title_full_unstemmed | Cancer vaccines as promising immuno-therapeutics: platforms and current progress |
title_short | Cancer vaccines as promising immuno-therapeutics: platforms and current progress |
title_sort | cancer vaccines as promising immuno-therapeutics: platforms and current progress |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931585/ https://www.ncbi.nlm.nih.gov/pubmed/35303904 http://dx.doi.org/10.1186/s13045-022-01247-x |
work_keys_str_mv | AT liujian cancervaccinesaspromisingimmunotherapeuticsplatformsandcurrentprogress AT fuminyang cancervaccinesaspromisingimmunotherapeuticsplatformsandcurrentprogress AT wangmanni cancervaccinesaspromisingimmunotherapeuticsplatformsandcurrentprogress AT wandandan cancervaccinesaspromisingimmunotherapeuticsplatformsandcurrentprogress AT weiyuquan cancervaccinesaspromisingimmunotherapeuticsplatformsandcurrentprogress AT weixiawei cancervaccinesaspromisingimmunotherapeuticsplatformsandcurrentprogress |